Physician profile
Melissa B Jones
NPI 1659660264
$884.87
in general payments reported to CMS, 2019-2025
12 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Behavioral Neurology & Neuropsychiatry provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $31.84 · 2022: $18.56 · 2023: $175 · 2024: $218 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $368.49 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Octapharma USA, INC. | $125.11 | 2023-2025 | Panzyga |
| Ironshore Pharmaceuticals INC. | $122.16 | 2024 | |
| Adlon Therapeutics L.P. | $62.45 | 2019-2020 | |
| Neos Therapeutics, Lp | $36.54 | 2019 | |
| Tempus Ai, INC | $34.57 | 2025 | Tempus Pixel |
| Harmony Biosciences LLC | $31.72 | 2025 | |
| Abbott Laboratories | $27.93 | 2023 | Amplatzer |
| Progenics Pharmaceuticals, INC. | $19.39 | 2025 | |
| Shire North American Group INC | $19.34 | 2019 | |
| Immedica Pharma US, INC. | $18.97 | 2023 | |
| Medline Industries Lp | $18.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.